Mental health in myasthenia gravis patients and its impact on caregiver burden.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 11 2022
Historique:
received: 02 02 2022
accepted: 10 10 2022
entrez: 12 11 2022
pubmed: 13 11 2022
medline: 16 11 2022
Statut: epublish

Résumé

Psychiatric comorbidities are relevant in patients with Myasthenia gravis (MG). Also, MG patients experience a reduced health-related quality of life (HRQoL). We aimed to quantify the impact of depression as well as self-perceived MG severity on HRQoL and caregivers' burden. In this cross-sectional study, we used a survey encompassing demographic, disease-related information, and standardized questionnaires to assess symptoms of depression, anxiety, HRQoL (MG Quality of Life scale; MG-QoL15), and caregiver burden (Burden Scale for Family Caregivers; BSFC). Data from 1399 participating patients (96%) and 1042 caregivers (65%) were eligible for further analysis. Symptoms of depression and anxiety disorder were indicated by 31% and 36% of patients. Self-reported MG severity (MG severity) and MG-QoL15 scores were strongly associated (estimated marginal means for severe versus mild MG severity = 18 95% CI [16; 21]; p ≤ 0.001). Adjusting for symptoms of depression decreased the estimated strength of this association (estimated marginal means for severe versus mild MG severity = 15 [13; 17]; p ≤ 0.001). Caregiver burden was associated to MG disease severity (estimated marginal means for severe vs. mild MG severity = 0.16 [0.13; 0,19); p ≤ 0.001) and also negatively influenced by symptoms of depression (estimated marginal means = 0.12 [0.09; 0.15]). Symptoms of depression and anxiety disorder in MG are frequent. Beyond MG severity, symptoms of depression have negative effects on HRQoL as well as on caregivers' burden. Diagnosis and treatment of psychiatric comorbidities should be considered an important element in MG care. Screening tools for mental health conditions should be implemented at least in specialized MG centers.

Identifiants

pubmed: 36369246
doi: 10.1038/s41598-022-22078-3
pii: 10.1038/s41598-022-22078-3
pmc: PMC9652470
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19275

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : Exc 257 NeuroCure

Informations de copyright

© 2022. The Author(s).

Références

J Clin Neurosci. 2018 Apr;50:41-44
pubmed: 29396072
Muscle Nerve. 2016 Dec;54(6):1015-1022
pubmed: 27220659
J Rehabil Med. 2018 Sep 28;50(9):769-778
pubmed: 30184240
J Neurosci Nurs. 2017 Apr;49(2):66-68
pubmed: 28277448
Eur Psychiatry. 2017 Mar;41:102-108
pubmed: 28135591
Cureus. 2020 Jul 14;12(7):e9184
pubmed: 32802619
Am J Kidney Dis. 1990 Jan;15(1):31-9
pubmed: 2294731
J Psychosom Res. 1999 Feb;46(2):155-64
pubmed: 10098824
Soc Sci Med. 2008 Mar;66(6):1334-45
pubmed: 18234406
CNS Drugs. 2007;21(6):473-81
pubmed: 17521227
J Neurol Sci. 2017 Jan 15;372:331-341
pubmed: 28017241
Muscle Nerve. 2011 Jan;43(1):14-8
pubmed: 21082698
Rev Neurol. 2000 Apr 16-30;30(8):712-5
pubmed: 10893733
Ther Adv Neurol Disord. 2008 Sep;1(2):36-51
pubmed: 21180568
BMC Neurol. 2010 Jun 18;10:46
pubmed: 20565885
J Clin Neuromuscul Dis. 2004 Sep;6(1):9-12
pubmed: 19078747
Arq Neuropsiquiatr. 2011 Apr;69(2A):176-9
pubmed: 21537555
Epilepsy Behav. 2005 May;6(3):303-11
pubmed: 15820336
Muscle Nerve. 2018 Feb 21;:
pubmed: 29466829
J Clin Neurosci. 2020 Sep;79:84-89
pubmed: 33070925
Neurology. 2021 Aug 10;:
pubmed: 34376512
Zhonghua Yi Xue Za Zhi. 2010 Dec 7;90(45):3176-9
pubmed: 21223762
Brain Behav. 2016 Aug 02;6(10):e00538
pubmed: 27781147
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Psychiatr Prax. 1992 Sep;19(5):157-63
pubmed: 1438610
Psychol Health. 2013;28(7):765-83
pubmed: 23343116
Nervenarzt. 2014 Jan;85(1):77-87
pubmed: 24441882
Psychosom Med. 1998 Mar-Apr;60(2):150-5
pubmed: 9560862
Autoimmunity. 2010 Aug;43(5-6):344-52
pubmed: 20380587
J Neurol. 2010 Sep;257(9):1473-81
pubmed: 20383521
Am J Psychiatry. 1999 Jun;156(6):908-11
pubmed: 10360131
Nervenarzt. 2008 May;79(5):577-86
pubmed: 18437339
Psychol Health Med. 2021 Feb;26(2):221-227
pubmed: 32877257
Health Qual Life Outcomes. 2010 Nov 11;8:129
pubmed: 21070628
Arch Neurol. 1993 Jun;50(6):617-20
pubmed: 8503799
Eur J Neurol. 2020 Jan;27(1):204-209
pubmed: 31408565
BMC Geriatr. 2014 Feb 20;14:23
pubmed: 24555474
Neurol Sci. 2012 Dec;33(6):1375-81
pubmed: 22875151
J Aging Health. 2005 Apr;17(2):125-47
pubmed: 15750048
Neurology. 1997 May;48(5):1253-60
pubmed: 9153452
N Engl J Med. 2016 Aug 11;375(6):511-22
pubmed: 27509100
BMJ Open. 2011 Dec 19;1(2):e000313
pubmed: 22184587
Health Qual Life Outcomes. 2015 Aug 01;13:115
pubmed: 26232146

Auteurs

Derin Marbin (D)

Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany. derin.marbin@charite.de.
Psychiatrische Universitätsklinik der Charité Im St. Hedwig-Krankenhaus, Berlin, Germany. derin.marbin@charite.de.

Sophie K Piper (SK)

Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt - Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Sophie Lehnerer (S)

Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Ulrike Harms (U)

Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Andreas Meisel (A)

Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH